182 related articles for article (PubMed ID: 33400854)
41. Small-molecule inhibitors of lysine methyltransferases SMYD2 and SMYD3: current trends.
Fabini E; Manoni E; Ferroni C; Rio AD; Bartolini M
Future Med Chem; 2019 Apr; 11(8):901-921. PubMed ID: 30998113
[TBL] [Abstract][Full Text] [Related]
42. Cooperation between SMYD3 and PC4 drives a distinct transcriptional program in cancer cells.
Kim JM; Kim K; Schmidt T; Punj V; Tucker H; Rice JC; Ulmer TS; An W
Nucleic Acids Res; 2015 Oct; 43(18):8868-83. PubMed ID: 26350217
[TBL] [Abstract][Full Text] [Related]
43. The lysine methyltransferase SMYD3 interacts with hepatitis C virus NS5A and is a negative regulator of viral particle production.
Eberle CA; Zayas M; Stukalov A; Pichlmair A; Alvisi G; Müller AC; Bennett KL; Bartenschlager R; Superti-Furga G
Virology; 2014 Aug; 462-463(100):34-41. PubMed ID: 25092459
[TBL] [Abstract][Full Text] [Related]
44. SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3.
Vieira FQ; Costa-Pinheiro P; Almeida-Rios D; Graça I; Monteiro-Reis S; Simões-Sousa S; Carneiro I; Sousa EJ; Godinho MI; Baltazar F; Henrique R; Jerónimo C
Oncotarget; 2015 May; 6(15):13644-57. PubMed ID: 25980436
[TBL] [Abstract][Full Text] [Related]
45. The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3.
Kunizaki M; Hamamoto R; Silva FP; Yamaguchi K; Nagayasu T; Shibuya M; Nakamura Y; Furukawa Y
Cancer Res; 2007 Nov; 67(22):10759-65. PubMed ID: 18006819
[TBL] [Abstract][Full Text] [Related]
46. SMYD3: a regulator of epigenetic and signaling pathways in cancer.
Bernard BJ; Nigam N; Burkitt K; Saloura V
Clin Epigenetics; 2021 Feb; 13(1):45. PubMed ID: 33637115
[TBL] [Abstract][Full Text] [Related]
47. Molecular Dynamics Simulations Reveal the Mechanisms of Allosteric Activation of Hsp90 by Designed Ligands.
Vettoretti G; Moroni E; Sattin S; Tao J; Agard DA; Bernardi A; Colombo G
Sci Rep; 2016 Apr; 6():23830. PubMed ID: 27032695
[TBL] [Abstract][Full Text] [Related]
48. Effect of the downregulation of SMYD3 expression by RNAi on RIZ1 expression and proliferation of esophageal squamous cell carcinoma.
Dong SW; Zhang H; Wang BL; Sun P; Wang YG; Zhang P
Oncol Rep; 2014 Sep; 32(3):1064-70. PubMed ID: 24993551
[TBL] [Abstract][Full Text] [Related]
49. Modulation of Human Hsp90α Conformational Dynamics by Allosteric Ligand Interaction at the C-Terminal Domain.
Penkler DL; Tastan Bishop Ö
Sci Rep; 2019 Feb; 9(1):1600. PubMed ID: 30733455
[TBL] [Abstract][Full Text] [Related]
50. Crystal structure of the middle and C-terminal domains of Hsp90α labeled with a coumarin derivative reveals a potential allosteric binding site as a drug target.
Peng S; Woodruff J; Pathak PK; Matts RL; Deng J
Acta Crystallogr D Struct Biol; 2022 May; 78(Pt 5):571-585. PubMed ID: 35503206
[TBL] [Abstract][Full Text] [Related]
51. ANKHD1 is required for SMYD3 to promote tumor metastasis in hepatocellular carcinoma.
Zhou Z; Jiang H; Tu K; Yu W; Zhang J; Hu Z; Zhang H; Hao D; Huang P; Wang J; Wang A; Xiao Z; He C
J Exp Clin Cancer Res; 2019 Jan; 38(1):18. PubMed ID: 30646949
[TBL] [Abstract][Full Text] [Related]
52. Histone methyltransferase SMYD3 promotes MRTF-A-mediated transactivation of MYL9 and migration of MCF-7 breast cancer cells.
Luo XG; Zhang CL; Zhao WW; Liu ZP; Liu L; Mu A; Guo S; Wang N; Zhou H; Zhang TC
Cancer Lett; 2014 Mar; 344(1):129-137. PubMed ID: 24189459
[TBL] [Abstract][Full Text] [Related]
53. Host factor SMYD3 is recruited by Ebola virus nucleoprotein to facilitate viral mRNA transcription.
Chen J; He Z; Yuan Y; Huang F; Luo B; Zhang J; Pan T; Zhang H; Zhang J
Emerg Microbes Infect; 2019; 8(1):1347-1360. PubMed ID: 31516086
[TBL] [Abstract][Full Text] [Related]
54. SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters.
Zhang H; Zheng Z; Zhang R; Yan Y; Peng Y; Ye H; Lin L; Xu J; Li W; Huang P
Cell Death Dis; 2021 Jul; 12(8):731. PubMed ID: 34301921
[TBL] [Abstract][Full Text] [Related]
55. SMYD3 controls a Wnt-responsive epigenetic switch for ASCL2 activation and cancer stem cell maintenance.
Wang T; Wu H; Liu S; Lei Z; Qin Z; Wen L; Liu K; Wang X; Guo Y; Liu Q; Liu L; Wang J; Lin L; Mao C; Zhu X; Xiao H; Bian X; Chen D; Xu C; Wang B
Cancer Lett; 2018 Aug; 430():11-24. PubMed ID: 29746925
[TBL] [Abstract][Full Text] [Related]
56. Exploring weak ligand-protein interactions by long-lived NMR states: improved contrast in fragment-based drug screening.
Buratto R; Mammoli D; Chiarparin E; Williams G; Bodenhausen G
Angew Chem Int Ed Engl; 2014 Oct; 53(42):11376-80. PubMed ID: 25196717
[TBL] [Abstract][Full Text] [Related]
57. The SMYD3 methyltransferase promotes myogenesis by activating the myogenin regulatory network.
Codato R; Perichon M; Divol A; Fung E; Sotiropoulos A; Bigot A; Weitzman JB; Medjkane S
Sci Rep; 2019 Nov; 9(1):17298. PubMed ID: 31754141
[TBL] [Abstract][Full Text] [Related]
58. Structure of human lysine methyltransferase Smyd2 reveals insights into the substrate divergence in Smyd proteins.
Xu S; Zhong C; Zhang T; Ding J
J Mol Cell Biol; 2011 Oct; 3(5):293-300. PubMed ID: 21724641
[TBL] [Abstract][Full Text] [Related]
59. Discovery of Novel Hsp90 C-Terminal Inhibitors Using 3D-Pharmacophores Derived from Molecular Dynamics Simulations.
Tomašič T; Durcik M; Keegan BM; Skledar DG; Zajec Ž; Blagg BSJ; Bryant SD
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962253
[TBL] [Abstract][Full Text] [Related]
60. SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9.
Cock-Rada AM; Medjkane S; Janski N; Yousfi N; Perichon M; Chaussepied M; Chluba J; Langsley G; Weitzman JB
Cancer Res; 2012 Feb; 72(3):810-20. PubMed ID: 22194464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
